Clorsulon (Curatrem)

Clorsulon is a sulfonamide-class flukicide developed specifically for the treatment and control of adult liver flukes (Fasciola hepatica) in cattle. Unlike macrocyclic lactones and benzimidazoles that target nematode parasites, clorsulon belongs to a distinct chemical class with selective activity against trematode (fluke) parasites. The drug addresses the significant economic and health impacts of fascioliasis—liver fluke disease—which affects cattle in temperate and tropical regions worldwide wherever the intermediate host snail populations and appropriate environmental conditions support fluke transmission. Clorsulon represents one of the limited pharmaceutical options available for fluke control in cattle, making it an important tool in integrated liver fluke management programs in endemic regions.

The mechanism of action of clorsulon involves inhibition of the glycolytic enzymes 3-phosphoglycerate kinase and phosphoglyceromutase within the liver fluke parasite. This disruption of energy metabolism depletes the fluke's ATP production, leading to paralysis and death of the parasite. The selective toxicity of clorsulon for fluke enzymes over mammalian homologs provides the safety margin that permits therapeutic use in cattle. Importantly, clorsulon is effective primarily against adult liver flukes residing in the bile ducts; activity against immature fluke stages is limited, which has implications for treatment timing relative to the fluke life cycle and the seasonal pattern of fluke transmission in endemic areas.

Clorsulon is commercially available in the United States primarily in combination with ivermectin as Ivomec Plus, which provides concurrent activity against liver flukes and the broad spectrum of nematodes and arthropods susceptible to ivermectin. The standalone product (Curatrem) containing only clorsulon is also available and may be preferred when fluke-specific treatment is desired without redundant nematode treatment. International markets may have additional formulations including oral drench products. The availability of clorsulon both as a standalone product and in combination expands treatment options for producers managing cattle in fluke-endemic regions.

FDA approval of clorsulon encompasses beef cattle and non-lactating dairy cattle, with specific withdrawal requirements that must be observed for food safety. The product addresses a parasitic challenge that can cause significant production losses including reduced weight gains, decreased milk production, condemnation of affected livers at slaughter, and in severe cases, acute mortality from massive fluke infection. Strategic use of clorsulon as part of integrated fluke management—combining pharmaceutical treatment with environmental management to reduce snail habitat and cattle exposure to infective metacercariae—provides the most effective approach to controlling fascioliasis in endemic herds.

Clorsulon is FDA-approved for the treatment and control of adult stages of the common liver fluke, Fasciola hepatica, in cattle. This indication addresses the economically significant condition of fascioliasis, which affects cattle production in regions with appropriate environmental conditions supporting the complex liver fluke life cycle. The life cycle requires freshwater snail intermediate hosts (primarily Galba truncatula and related species) and wet, low-lying pasture areas where metacercariae (the infective stage) can develop and persist on vegetation. Endemic regions include the Pacific Northwest, Gulf Coast states, and areas of the Northeast in the United States, as well as extensive regions in Europe, South America, Australia, and other temperate and tropical areas worldwide.

The primary economic impacts of liver fluke infection that clorsulon treatment addresses include reduced feed efficiency and weight gains, decreased milk production in dairy cattle, condemnation of affected livers at slaughter inspection, poor body condition, and reproductive inefficiency. Heavy infections can cause acute fascioliasis with sudden death, particularly in young cattle exposed to massive numbers of immature flukes migrating through the liver. Chronic fascioliasis from adult flukes residing in bile ducts causes ongoing liver damage, bile duct fibrosis, and progressive production losses. Strategic clorsulon treatment reduces adult fluke burdens, minimizing both individual animal health impacts and pasture contamination through egg shedding.

Clorsulon's activity is specifically directed against adult liver flukes located in the bile ducts; efficacy against immature fluke stages migrating through the liver parenchyma is limited. This stage-specific activity has important implications for treatment timing. Adult flukes become established in bile ducts approximately 10-12 weeks after cattle ingest metacercariae from contaminated pasture. Treatment during the early fall, before adult flukes reach peak egg production, can reduce pasture contamination for the following grazing season. Treatment in late winter or early spring eliminates flukes acquired during the preceding grazing season before they contribute significantly to cumulative liver damage.

The combination product Ivomec Plus (ivermectin/clorsulon) provides concurrent treatment of liver flukes along with the extensive nematode and arthropod spectrum covered by ivermectin. This combination is particularly valuable in regions where cattle face both fluke and nematode challenges, as it allows comprehensive parasite control with a single treatment. However, in situations where nematode treatment is not needed or when managing for nematode anthelmintic resistance, the standalone clorsulon product (Curatrem) permits fluke-specific treatment without unnecessary macrocyclic lactone exposure that could contribute to nematode resistance selection.

Extra-label use of clorsulon in sheep and goats may be considered under veterinary supervision in fluke-endemic regions where few approved alternatives exist for small ruminants. However, such use requires establishment of appropriate withdrawal times through consultation with resources such as the Food Animal Residue Avoidance Databank (FARAD), and the efficacy in small ruminant species may differ from cattle. Integrated fluke management combining pharmaceutical treatment with environmental modifications to reduce snail habitat and minimize cattle access to high-risk wet pasture areas provides the most sustainable approach to controlling fascioliasis in endemic regions.

The standard dose of clorsulon for cattle is 7 mg per kilogram of body weight (7 mg/kg) when administered as a subcutaneous injection. Using the Curatrem injectable formulation containing 84 mg/mL clorsulon, this equates to 1 mL per 12 kg (approximately 26 pounds) of body weight. The injection should be administered subcutaneously, preferably in the neck region anterior to the shoulder, using appropriate injection technique to minimize tissue reactions. Accurate body weight determination through scales or validated weight estimation methods ensures appropriate dosing; underdosing may result in reduced efficacy against fluke populations while overdosing increases the risk of adverse effects.

When clorsulon is administered via the combination product Ivomec Plus (ivermectin 1%/clorsulon 10%), the standard dose of 1 mL per 50 kg (110 pounds) of body weight delivers the appropriate dose of both active ingredients—200 mcg/kg ivermectin and 2 mg/kg clorsulon. Note that the clorsulon dose in the combination product (2 mg/kg) is lower than the standalone Curatrem dose (7 mg/kg), which reflects the synergistic or additive effects of the combination for fluke control rather than independent clorsulon activity at the lower dose. The choice between standalone clorsulon and the combination product should be based on whether concurrent nematode treatment is indicated.

Proper injection technique optimizes drug delivery and minimizes injection site reactions. Subcutaneous injection in the neck is preferred to other anatomical sites to minimize any potential impact on carcass value from injection site lesions. Needles should be of appropriate gauge (16-18 gauge) and length (0.5-1 inch) for the size of animal being treated. Single-use needles are recommended; if needles must be reused, they should be changed frequently to maintain sharpness and minimize contamination risk. Maximum injection volume per site should be observed per label directions, with multiple sites used for larger doses in heavy animals.

Treatment timing should be strategically planned based on the liver fluke life cycle and regional epidemiology. Adult flukes become established in bile ducts approximately 10-12 weeks after cattle ingest metacercariae, and clorsulon is effective against these adult stages. In most endemic regions, strategic treatment in late fall (October-November) addresses flukes acquired during the summer grazing season before they reach maximum egg production. A second treatment in late winter or early spring (February-March) can eliminate flukes that matured during winter and prepares cattle for the upcoming grazing season with reduced fluke burdens. The specific timing should be adapted to local conditions and the particular fluke transmission pattern in each endemic area.

For herds in heavily endemic areas or those with history of significant fluke problems, fecal sedimentation testing to detect fluke eggs can help guide treatment decisions and assess treatment efficacy. Egg counts obtained 8-12 weeks post-treatment can indicate whether treatment was successful in eliminating adult flukes. Negative egg counts following treatment suggest treatment success, while persistent egg shedding may indicate need for retreatment or consideration of resistance concerns, though clorsulon resistance has not been widely reported.

Withdrawal times must be strictly observed to prevent violative drug residues in meat. Cattle treated with clorsulon (Curatrem) must not be slaughtered for human consumption for 8 days following treatment. For the combination product Ivomec Plus, the withdrawal period is determined by the ivermectin component at 35 days. Clorsulon is not approved for use in female dairy cattle of breeding age or in veal calves. Use in lactating dairy cattle is prohibited due to the absence of established milk withdrawal times. These restrictions apply regardless of the fluke burden or clinical indication for treatment.

Clorsulon demonstrates a favorable safety profile in cattle when administered according to label directions at the recommended dose. The selective inhibition of fluke-specific glycolytic enzymes rather than mammalian homologs provides the margin of safety that permits therapeutic use. Clinical trials supporting FDA approval established that adverse effects are uncommon at the recommended dose of 7 mg/kg, and extensive field use has confirmed the acceptable safety profile in the target species. However, as with all pharmaceutical products, understanding potential adverse effects enables appropriate monitoring and management of treated cattle.

Transient injection site reactions are the most commonly reported adverse effect following subcutaneous clorsulon administration. Local swelling at the injection site may occur and typically resolves within days to weeks without intervention. The reaction reflects tissue response to the drug vehicle and injection trauma rather than systemic toxicity. Proper injection technique—subcutaneous rather than intramuscular placement, appropriate needle selection, aseptic procedures, and adherence to recommended volumes per site—minimizes the incidence and severity of injection site reactions. In cattle destined for slaughter, injection site selection in the neck region ensures any tissue reaction has minimal carcass impact.

At recommended doses, systemic adverse effects are uncommon. Clorsulon has a relatively wide margin of safety in cattle, with acute toxicity studies demonstrating that doses several times the recommended therapeutic dose are required to produce significant adverse effects. However, substantial overdosing could potentially cause gastrointestinal disturbances, depression, or other signs of toxicity. Accurate weight estimation and dose calculation prevent accidental overdosing that could increase adverse effect risk. If signs suggestive of toxicity are observed following treatment, supportive care should be provided while the drug is eliminated.

A phenomenon known as post-treatment reaction may occur when treating heavily fluke-infected cattle, particularly those with very high burdens of adult flukes in the bile ducts. The death of large numbers of adult flukes within the biliary system can cause local inflammatory responses, temporary bile duct obstruction by dying parasites and debris, and release of fluke antigens that may provoke systemic inflammatory responses. Clinically, this may manifest as transient depression, reduced appetite, or mild colic signs in the days following treatment. In most cases, these reactions are self-limiting and resolve without intervention. Providing supportive care and monitoring affected animals until resolution is appropriate.

Interactions between dying flukes and hepatic tissue can occasionally cause more significant reactions in heavily parasitized animals. The migrating immature flukes cause tissue damage during their journey through the liver parenchyma, and this damaged tissue may be more susceptible to complications as adult flukes die in the bile ducts and are broken down. In severely affected animals, more pronounced signs of hepatic distress may occur. Treatment of heavily parasitized animals should include close monitoring for several days post-treatment, with provision of supportive care as needed. Strategic treatment before fluke burdens reach extreme levels helps prevent severe post-treatment reactions.

Clorsulon is contraindicated for use in female dairy cattle of breeding age due to the absence of established milk withdrawal times following treatment. This restriction applies regardless of current lactation status—replacement dairy heifers and dry dairy cows are also excluded from approved use. The prohibition reflects food safety requirements regarding drug residues in milk rather than evidence of specific harm from milk containing clorsulon residues. Dairy producers in fluke-endemic regions requiring fluke treatment in animals destined for the milking herd must carefully evaluate alternatives or time treatment relative to the animal's production cycle to maintain compliance.

Use of clorsulon in calves intended for veal production is not approved when withdrawal time constraints cannot be accommodated. The 8-day meat withdrawal for standalone clorsulon (or 35 days for the ivermectin combination product) must be considered relative to the expected marketing timeline for veal calves. In fluke-endemic regions where veal production occurs, treatment decisions should balance the potential production benefits of fluke control against the regulatory constraints of withdrawal times. Consultation with a veterinarian can help identify appropriate management approaches.

Animals with known hypersensitivity to clorsulon or related sulfonamide compounds should not receive clorsulon treatment. While allergic reactions to clorsulon are rarely reported, animals that have demonstrated adverse reactions to previous clorsulon treatment or to other sulfonamide-class compounds should be excluded from further treatment with clorsulon. Alternative flukicides such as albendazole (where approved for fluke indications) or management approaches that minimize fluke exposure may be appropriate for such animals.

Severely debilitated cattle or those with significant pre-existing hepatic compromise warrant careful evaluation before clorsulon treatment. Cattle with acute fascioliasis from massive immature fluke migration may have severely damaged livers that could be further stressed by the death of adult flukes in bile ducts and the associated inflammatory response. In such cases, providing supportive care to stabilize the animal before flukicide treatment, or accepting that treatment may provoke temporary worsening before improvement, should be discussed with a veterinarian. Treatment decisions for severely compromised animals should consider individual circumstances and the risk-benefit balance of immediate treatment versus supportive care followed by delayed treatment.

The most common drug combination involving clorsulon is its formulation with ivermectin in the combination product Ivomec Plus. This intentional combination provides concurrent activity against liver flukes (via clorsulon) and the extensive nematode and arthropod spectrum of ivermectin. The combination has been studied for safety and efficacy, with the two active ingredients providing complementary activity without adverse interaction. However, when using the combination product, all precautions and contraindications applicable to both ivermectin and clorsulon must be observed, including the prohibition on use in lactating dairy cattle and the 35-day meat withdrawal determined by the ivermectin component.

When clorsulon treatment is being considered for cattle already receiving other medications, potential interactions should be evaluated. Clorsulon is a sulfonamide-class compound, and while it is distinct from antibacterial sulfonamides in its antiparasitic application, potential exists for interaction with other sulfonamide drugs. Concurrent administration with sulfonamide antibiotics is uncommon in routine cattle practice but could theoretically result in additive effects. Cattle receiving sulfonamide medications for bacterial infections should have clorsulon treatment timing coordinated with veterinary guidance.

Hepatic metabolism of clorsulon suggests potential for interaction with other drugs metabolized by or affecting liver enzyme systems. Drugs that induce or inhibit hepatic cytochrome P450 enzymes could theoretically affect clorsulon pharmacokinetics, though specific interactions have not been extensively studied in cattle. When clorsulon treatment is planned for cattle receiving concurrent medications, particularly those known to affect hepatic metabolism, veterinary consultation regarding potential interactions is advisable. This is particularly relevant for valuable breeding stock or cattle receiving multiple medications for concurrent conditions.

Vaccination timing relative to clorsulon treatment has not been specifically studied, but general principles suggest that separating flukicide treatment from vaccination by 48-72 hours when feasible may be prudent. The stress of handling for treatment, potential for mild post-treatment reactions, and theoretical immunomodulatory effects of drug treatment support this conservative approach. However, when practical management requires concurrent treatment and vaccination—such as during fall processing of cattle that will not be handled again before winter—the benefits of comprehensive health management generally outweigh theoretical interaction concerns.

Human safety precautions during clorsulon handling and administration minimize occupational exposure risk. Personnel handling and administering clorsulon should wear protective gloves to prevent skin contact with the product. Direct contact with skin or eyes should be avoided; if contact occurs, the affected area should be washed immediately with soap and water, and eyes should be flushed thoroughly with clean water if ocular exposure occurs. Medical attention should be sought if irritation persists following exposure. Personnel with known sensitivity to sulfonamide compounds should avoid handling clorsulon products. Standard needlestick precautions apply when using injectable formulations, and sharps should be disposed of appropriately.

Food safety and residue avoidance require strict adherence to established withdrawal times. Cattle treated with standalone clorsulon (Curatrem) must not be slaughtered for human consumption for 8 days following treatment. For the ivermectin/clorsulon combination product (Ivomec Plus), the withdrawal period is 35 days, determined by the ivermectin component. Treated animals should be clearly identified and withdrawal dates documented to prevent inadvertent premature slaughter. Use in lactating dairy cattle is prohibited at all times due to absence of established milk withdrawal. These food safety requirements apply regardless of the severity of fluke infection or the clinical necessity for treatment.

Integrated fluke management combining pharmaceutical treatment with environmental and management approaches provides more sustainable control than reliance on drug treatment alone. Liver fluke transmission requires freshwater snail intermediate hosts and wet pasture conditions where metacercariae can develop and persist. Reducing snail habitat through drainage improvements, fencing cattle away from wet areas and snail habitats, and managing grazing to minimize exposure during high-risk periods all contribute to reduced fluke challenge. Pharmaceutical treatment with clorsulon is most effective when integrated with these management practices rather than used as a standalone control measure.

Treatment efficacy monitoring through fecal sedimentation testing helps assess clorsulon effectiveness and detect potential resistance development. While clorsulon resistance in liver flukes has not been widely documented to date, monitoring treatment outcomes supports early detection of emerging resistance. Fecal samples collected 8-12 weeks post-treatment (allowing time for existing eggs to clear and adult flukes to re-establish if treatment failed) provide assessment of treatment success. Persistent egg shedding following appropriately timed treatment may indicate need for retreatment, incorrect timing relative to the fluke life cycle, or emerging resistance concerns warranting veterinary consultation.

Proper treatment timing maximizes clorsulon efficacy given its activity spectrum limited to adult flukes. Treating before flukes reach maturity (less than 10-12 weeks post-infection) will not eliminate immature stages migrating through the liver. Conversely, treating during periods of active fluke transmission may eliminate existing adults but leave the animal susceptible to new infections from continued metacercariae exposure. Strategic treatment timing based on local fluke epidemiology—typically late fall and/or late winter/early spring in temperate regions—optimizes the benefit of clorsulon treatment within integrated fluke management programs.

Clorsulon products should be stored according to manufacturer specifications to maintain product stability and efficacy throughout the labeled shelf life. Injectable formulations should be stored at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), protected from direct sunlight and extreme temperature fluctuations. The product should not be frozen, as freezing may affect product consistency or potency. Storage areas should provide protection from the temperature extremes common in uninsulated agricultural buildings or vehicles. Verification of appropriate storage conditions through periodic temperature monitoring supports product quality assurance.

Multi-dose container handling requires attention to aseptic technique to prevent contamination that could affect product quality or cause injection site infections in treated animals. The rubber stopper should be cleaned with alcohol or appropriate disinfectant before each needle entry. Needles should be replaced frequently rather than using a single needle for multiple vial entries, which can dull the needle, introduce contaminants, and damage the stopper. Multi-dose vials should be used within the timeframe specified by the manufacturer once the vial seal is first penetrated; recording the date of first opening on the container supports appropriate use timelines. Partially used vials should be examined before each use for any signs of contamination, discoloration, or precipitation.

Disposal of clorsulon products and associated materials must comply with applicable federal, state, and local regulations. Empty containers should be triple-rinsed before disposal, with rinsate collected and disposed of appropriately rather than released into the environment. Containers should be rendered non-reusable by puncturing or crushing before disposal through appropriate waste channels. Used needles and syringes should be placed in designated sharps containers and disposed of through medical waste programs. Unused or expired product should be disposed of through veterinary pharmaceutical return programs, agricultural chemical collection events, or hazardous waste facilities where available. Product should not be disposed of through regular trash, drains, or in any manner that could result in environmental contamination or unintended exposure.

Production type considerations—specifically the dairy versus beef distinction—represent the primary factor affecting clorsulon use decisions across cattle populations. Dairy breeds managed for milk production, including Holstein, Jersey, Brown Swiss, Guernsey, Ayrshire, and similar breeds, face significant restrictions on clorsulon use. The product is not approved for use in female dairy cattle of breeding age regardless of lactation status, effectively excluding the entire milking herd and replacement heifer inventory from treatment. Dairy producers in fluke-endemic regions face challenging management decisions, as liver fluke infection can significantly impact milk production, but pharmaceutical treatment options are limited by the milk residue concerns.

Beef cattle breeds may receive clorsulon according to label directions without breed-specific restrictions, making fluke control more straightforward in beef operations. The 8-day meat withdrawal for standalone clorsulon (or 35 days for the ivermectin combination) must be observed, but this is readily accommodated in typical beef production timelines. Body condition variation among breeds and individuals should be considered when estimating weights for dose calculation; accurate dosing ensures optimal efficacy against adult fluke populations. Breeds commonly grazed in wet, low-lying pastures with high fluke risk—such as those in Pacific Northwest ranching systems or Gulf Coast grazing operations—may benefit from strategic clorsulon treatment as part of integrated fluke management.

Dual-purpose cattle and those transitioning between production systems require careful attention to use restrictions. Animals managed as dairy cattle are subject to dairy restrictions; if such animals are removed from dairy production and transitioned to beef production, the regulatory status changes, but appropriate records and withdrawal time observance remain essential. Similarly, dairy steers raised for beef production are not subject to dairy use restrictions and may receive clorsulon treatment according to beef cattle label directions.

Geographic and management factors often outweigh breed considerations in determining clorsulon treatment needs. Cattle of any breed grazing in fluke-endemic areas with appropriate snail habitat and environmental conditions are at risk for fascioliasis. Risk assessment based on regional fluke prevalence, pasture characteristics, history of fluke problems in the herd, and inspection findings at slaughter (liver condemnation rates) provides better guidance for treatment decisions than breed alone. Herds in low-risk areas may never require flukicide treatment regardless of breed, while herds in endemic areas benefit from strategic clorsulon use integrated with environmental management to reduce fluke challenge.

Within the flukicide category, limited pharmaceutical alternatives to clorsulon are available for cattle in the United States. Albendazole (Valbazen) demonstrates activity against liver flukes when used at the higher dose labeled for fluke treatment, providing an alternative chemical class option. However, albendazole is not approved for use in lactating dairy cattle and carries specific restrictions regarding use in early pregnancy due to teratogenic potential. The benzimidazole mechanism of albendazole (microtubule inhibition) differs from clorsulon's glycolytic enzyme inhibition, providing potential for alternation between classes if resistance concerns emerge. International markets may have additional flukicide options including triclabendazole, which has activity against immature fluke stages that clorsulon lacks.

The combination product Ivomec Plus (ivermectin/clorsulon) provides concurrent activity against liver flukes and the broad nematode and arthropod spectrum of ivermectin. This combination is particularly valuable when cattle face both fluke and nematode challenges, common in many grazing situations in endemic regions. The ivermectin component provides the familiar macrocyclic lactone activity against gastrointestinal roundworms, lungworms, grubs, lice, and mites, while clorsulon addresses the liver fluke infection. When both parasite types are present, the combination offers efficient single-treatment control; when only fluke treatment is needed, standalone clorsulon avoids unnecessary macrocyclic lactone exposure.

Integrated fluke management often incorporates pharmaceutical treatment with management practices that reduce fluke transmission. While not pharmaceutical alternatives, approaches such as drainage improvements to reduce snail habitat, fencing cattle from wet areas where snails concentrate, and strategic grazing management to minimize metacercariae exposure complement flukicide treatment. These practices reduce the frequency of pharmaceutical treatment required and provide more sustainable long-term fluke control than drug treatment alone. Combining appropriate flukicide treatment timing with environmental management addresses both existing fluke infections and ongoing transmission pressure, providing comprehensive fascioliasis control in endemic herds.